Analytical validation of HRD calculation performed with the OncoDEEP® Kit Comprehensive Genomic Panel


This poster highlights the results of a rigorous study conducted on 76 ovarian carcinoma samples from four Spanish hospitals. The OncoDEEP® kit stands out for its ability to analyze 638 genes and provide critical genomic signatures such as Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and HRD.

The validation results demonstrate an overall concordance of 88.8% with a sensitivity of 90% and specificity of 88% compared to gold standard references, confirming the effectiveness of the OncoDEEP® kit in identifying ovarian cancer patients eligible for PARP inhibitor therapy. By combining the analysis of BRCA1/2 status and genomic markers such as Loss of Heterozygosity (LOH), Allelic Disparity on Telomeres (ADT), and Large-scale Rearrangements (LR), the kit offers a comprehensive solution for tumor characterization, reducing both costs and processing time.

Explore this poster to understand how the OncoDEEP® kit is revolutionizing the detection of genomic signatures and improving patient management through advanced technology and dedicated bioinformatics analyses.

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Table 1.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

You may also be interested in these resources

Scientific Application Note

COVID-19 PANDEMIC: Modelling from the US National Cancer Institute (NCI) predicts the pandemic will result in an excess of over 10,000 deaths from breast and colorectal cancer in the USA, due to missed screening and delayed therapy.

COVID-19 and CANCER With the spread of coronavirus disease 2019 (COVID-19), countries and states have instituted lockdowns. These decisions have been difficult and are sometimes described as benefiting the public health at the expense of...

Scientific Application Note

HEPATOCELLULAR CANCER Combination PD-L1 and VEGFR inhibition (atezolizumab plus bevacizumab) delivered better overall and progression-free survival than standard of care sorafenib in a pivotal phase 3 study.

ATEZOLIZUMAB PLUS BEVACIZUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA Richard S. Finn et al N Engl J Med 2020; 382:1894-1905 BACKGROUND The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b...

Share This